Catherine Douthwright, PhD
Neuromuscular Clinical Research Program Director
UMass Chan Medical School
Worcester, MA
Robert H. Brown Jr., MD, DPhil
Margaret Ayo Owegi, DO
Mehdi Ghasemi, MD, MPH
Catherine Douthwright, PhD
Hajar Houmani, DNP
Reylyn Tanchiatco
The goal of the HEALEY ALS Platform Trial is to screen drugs rapidly and efficiently, get solid answers, and determine next steps.
Informational Webinars about Regimen E

Trehalose/SLS-005 Drug Science and Mechanism of Action Q&A Webinar
Hosted by Seelos Therapeutics on 10 March 2022

Recording Available!
Recording available under “science and mechanism of action series”

The ALS Association/Northeast ALS Consortium Educational Webinar
Update on Healey ALS Platform Trial Regimen E: Trehalose for ALS

UPDATE ON REGIMEN E
TREHALOSE FOR ALS

Recording Available!
https://bit.ly/3X2u004
Recording available under “educational webinars” on neals.org
58 Sites Currently Activated for Regimen E

(as of 12/1/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!
Enrollment Updates (as of Dec 1, 2022)

• 171 individuals have signed informed consent

• 127 individuals have been randomized within Regimen E

Thank You

This breakthrough trial would not be possible without your participation

Your partnership in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:
https://bit.ly/3r6Nd2L

ALS Link sign-up:
https://bit.ly/3o2Ds3m

Upcoming Webinars:
December 8th- Mia Resendes (Primary Coordinator, Mass General Hospital)